Menu
Search
|

Menu

Close
X

Edge Therapeutics Inc EDGE.OQ (NASDAQ Stock Exchange Global Select Market)

13.70 USD
-0.25 (-1.79%)
As of 1:21 AM IST
chart
Previous Close 13.95
Open 13.68
Volume 20,195
3m Avg Volume 23,668
Today’s High 13.92
Today’s Low 13.46
52 Week High 14.40
52 Week Low 7.44
Shares Outstanding (mil) 30.85
Market Capitalization (mil) 340.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.230
FY16
-1.345
FY15
-1.900
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.04
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
23.99
16.52
LT Debt to Equity (MRQ)
vs sector
20.32
12.22
Return on Investment (TTM)
vs sector
-43.75
14.43
Return on Equity (TTM)
vs sector
-48.11
16.13

EXECUTIVE LEADERSHIP

Sol Barer
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Brian Leuthner
President, Chief Executive Officer, Director, Since
Salary: $467,500.00
Bonus: --
Isaac Blech
Independent Vice Chairman of the Board, Since
Salary: --
Bonus: --
Andrew Saik
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Daniel Brennan
Chief Operating Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

300 Connell Dr Ste 4000
BERKELEY HEIGHTS   NJ   07922-2817

Phone:

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

SPONSORED STORIES